StockNews.com initiated coverage on shares of Infinity Pharmaceuticals (NASDAQ:INFI – Free Report) in a report released on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.
Infinity Pharmaceuticals Price Performance
Infinity Pharmaceuticals stock opened at $0.09 on Friday. The firm has a 50 day simple moving average of $0.14 and a 200-day simple moving average of $0.18. The stock has a market capitalization of $8.03 million, a PE ratio of -0.21 and a beta of 1.38. Infinity Pharmaceuticals has a 12-month low of $0.08 and a 12-month high of $1.51.
Infinity Pharmaceuticals (NASDAQ:INFI – Get Free Report) last posted its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter. The firm had revenue of $0.58 million for the quarter.
Institutional Trading of Infinity Pharmaceuticals
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors.
- Five stocks we like better than Infinity Pharmaceuticals
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- These Quality Dividend Kings Grow their Dividends the Fastest
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- 3 Growth Stocks to Buy in September
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 Underappreciated Stocks with Nowhere to Go But Up
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.